Diskgen Intervertebral Jun 2026

IDCT (rebonuputemcel) is a first-in-class, allogeneic ("off-the-shelf") cell therapy designed to treat symptomatic, single-level lumbar degenerative disc disease (DDD).

DiskGen is an designed to treat symptomatic, mild-to-moderate lumbar disc degeneration. Unlike standard treatments that merely manage symptoms, DiskGen aims to address the underlying pathophysiology of the disc by regenerating it from the inside out. diskgen intervertebral

This report summarizes the current status of (Injectable Disc Cell Therapy), an investigational regenerative treatment for intervertebral disc degeneration (IDD) developed by DiscGenics . Overview of DiscGenics IDCT IDCT (rebonuputemcel) is a first-in-class

While DiskGen represents a leap forward in technology, it is not suitable for every back pain patient. Ideal candidates generally meet the following criteria: diskgen intervertebral